Bronchial arterial infusion in combination with take icotinib hydrochloride orally for treatment of advanced non-small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15006795

Enrollment

Unknown

Registered

2015-07-22

Start date

2014-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

experimental group:Bronchial arterial infusion in combination with take icotinib hydrochloride orally

Control group:solo bronchial arterial infusion

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients enrolled in this study had histologically proven advanced NSCLC; 2. EGFR genes mutation; 3. Patients were ineligible for surgical resection; 4. Patients had to be 18 years of age or older and were required to have Karnofsky performance status of 70 or more, with a life expectancy more than 3 months; 5. All patients signed a consent form approved by the Institutional Review Board Committee before the enrollment.

Exclusion criteria

Exclusion criteria: 1. having received chemotherapy,radiotherapy, or other anti-tumor therapy before study treatments; 2. with a life expectancy shorter than 3 months; 3. pregnant or nursing patients, patients with uncontrolled serious infections, and patients with acute or chronic respiratory distress were excluded for the enrollment.

Design outcomes

Primary

Measure	Time frame
tumor volume;	—

Secondary

Measure	Time frame
CEA;NSE;CYFRA21-1;	—

Countries

China

Contacts

Public ContactGuan Yongsong

yongsongguan@126.com+86 18980601787

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026